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Abstract: This paper investigates the impact of fast parameter identification methods, which do not require any forward 
simulations, on model-based glucose control, using retrospective data in the Christchurch Hospital Intensive Care Unit. 
The integral-based identification method has been previously clinically validated and extensively applied in a number of 
biomedical applications; and is a crucial element in the presented model-based therapeutics approach. Common non-linear 
regression and gradient descent approaches are too computationally intense and not suitable for the glucose control appli-
cations presented. The main focus in this paper is on better characterizing and understanding the importance of the inte-
gral in the formulation and the effect it has on model-based drug therapy control. As a comparison, a potentially more 
natural derivative formulation which has the same computation speed advantages is investigated, and is shown to go un-
stable with respect to modelling error which is always present clinically. The integral method remains robust. 
1. INTRODUCTION 
 Therapy guidance using physiological models is a grow-
ing trend in bio-engineering [1-8]. In general, the idea is to 
use parameter identification to identify patient specific pa-
rameters then use these parameters to predict future dynam-
ics, and in particular, individual patient response to therapy. 
For example, glucose control in the intensive care unit 
(ICU), has been dramatically improved by using a glucose-
insulin model to optimize insulin doses and changes of nutri-
tion [2, 9-14]. A glucose control protocol SPRINT (special-
ized reduced insulin nutrition table) has changed clinical 
practice in the Christchurch Intensive Care Unit [14]. The 
result is tight control of blood glucose with a 32% mortality 
reduction. Parameter identification is thus an important part 
of the overall process, as the identified parameters affect the 
overall therapy prediction. There are many methods for pa-
rameter identification, most of which are some variation of 
the standard non-linear regression [15]. These methods in-
clude gradient descent [16, 17], Bayesian with many starting 
points [18, 19] and hybrid approaches [20, 21]. 
 The problem with these standard non-linear regression 
approaches is that they all typically require many forward 
solutions and starting points to ensure robustness. In a 
model-based therapeutics approach [2, 9-14] parameter iden-
tification can occur every 1-2 hours over periods of up to one  
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or several weeks, for many patients. A Monte Carlo method, 
taking into account sensor error and error in fixed population 
parameters to optimize therapy selection, also significantly 
increases the number of parameter identifications required 
each time. Similar Monte Carlo approaches to optimizing 
such protocols in a virtual patient simulated trial [10, 14, 22] 
are also computationally intense for the same reasons. 
 An integral-based parameter identification method has 
been developed [23] and extended to other physiological 
systems [24-27], that avoids the need for any forward simu-
lations. It can thus dramatically reduce the computation re-
quired. These integral methods are therefore well suited to 
model-based control applications requiring real-time parame-
ter identification. For example, agitation sedation control 
[28, 29], fluid therapy and inotropic drug administration for 
improved cardiac management [25] and control of neuro-
muscular blockade in general anaesthesia [21, 30]. This pa-
per investigates different computationally fast formulations 
that don’t require forward simulations and in particular ex-
amines the impact of these methods on physiological model-
based glucose control. 
 These issues are illustrated and tested with respect to 
noise and modelling error using an exemplar glucose-insulin 
model that has been extensively validated over many clinical 
trials [2, 9-14, 22, 23, 31-40]. The glucose-insulin model and 
methods are tested using retrospective clinical data. Several 
practical issues that arise in clinical implementation are ad-
dressed, to highlight issues of performance and stability. 
 Finally, a new model-based control method for metabolic 
control is presented, that combines a non-invasive continu-
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ous glucose sensor (CGMS) [41] with current standard glu-
cometer sensors [42]. This method is shown to provide a 
potentially significant improvement in glucose control in 
simulation that warrants further clinical investigation in the 
future. 
2. METHODOLOGY 
2.1. Glucose-Insulin Model 
 The glucose-insulin model is defined [11-13, 23]: 
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where G(t) is the plasma glucose concentration (mmol/L); 
GE the equilibrium level of plasma glucose concentration 
(mmol/L); Q(t) the interstitial insulin; I(t) the concentration 
of the plasma insulin above basal level (mU/L); P(t) the ex-
ogenous glucose infusion rate (mmol/(L min)); u(t) the insu-
lin infusion rate (mU/min); V the assumed insulin distribu-
tion volume (L); n the delay in interstitial transfer of insulin 
(min
-1
); pG the fractional clearance of plasma glucose at ba-
sal insulin (min
-1
); SI the time-varying insulin sensitivity 
(L/mU min); k the parameter controlling the effective half 
life of insulin (min
-1
); and ?G  the Michaelis-Menten pa-
rameter for glucose clearance saturation. For more details on 
the construction and physiological interpretation of the 
model Equations (1)-(3) see [11-13, 23]. 
2.2. Parameter Identification 
2.2.1. Integral Method 
 For the glucose-insulin Equations (1)-(3), a similar inte-
gral-based parameter identification method to [23] is applied. 
The parameters ?G , k, n and pG in Equations (1)-(3) are held 
constant at the population values based on prior studies and 
sensitivity analysis [23]: 
?G = 165 , k = 0.0099, n = 0.16, pG = 0.01          (5) 
 Similarly, the parameter GE is held at the mean glucose 
of each patient. The nutritional carbohydrate input appear-
ance rate, P(t) in Equations (1) and (4) is also held constant, 
but may change with respect to time for different patients. 
The exogenous insulin u(t) is defined: 
u(t) = uI + uB , 0 ? t ? 1
= uI , 1 ? t ? 60             (6) 
where uI (mU/min) is the constant infusion rate over 1 hour 
and uB (mU/min) is the amount of bolus given over one min-
ute. The parameter SI is insulin sensitivity and is assumed 
unknown. Integrating Equation (1) from 0 to t yields: 
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G
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I
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Q
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 Choosing n values of time, 
 
t = t1,…, tn , ?[0, 60],  where 
 
0 < t1 <? < tn , a set of n equations are formulated: 
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where Q(t) is defined in Equation (8). To avoid any error in 
G(0) potentially propagating through the equations, G0 = 
G(0) is assumed unknown and is identified along with SI. 
Equations (9) can be written as a matrix system: 
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where G is a continuous approximation to the measured 
glucose [23] and the integrals are evaluated by the trapezium 
rule. Equation (10) can be solved by linear least squares to 
determine SI as a constant over any period. Thus, 
 
S
I
 may be 
identified as piecewise constant. 
 For glucose control in the Intensive Care Unit (ICU), 
Equation (1) is utilized over periods of 1 hour [11, 13] and 
glucose is measured on the hour. For two glucose measure-
ments G0 = G(0) and G60 = G(60) , the function G(t) in 
Equation (10) can be approximated by a straight line [23]. 
For a given infusion uI or bolus uB in Equation (6), 
nutritional input P(t) and glucose measurements G0 and G60, 
the solution to Equation (10) determines the required insulin 
sensitivity. However, note that a similar approach could be 
used if glucose is measured more frequently. 
2.2.2. Similar Approach with the Derivative 
 A similar, potentially simpler, approach to the parameter 
identification of Equations (7)-(10) is to use the original 
differential Equations (1)-(3), rather than an integral 
formulation. For a given set of values, 
 
t = t0 ,…, tn , n+1 
equations can be formulated: 
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where t0=0. The analogous matrix system to Equation (10) is 
defined: 
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where 
 
?G(ti ) are determined by standard finite differences. 
Equation (12) can be solved by linear least squares to deter-
mine SI. 
94    The Open Medical Informatics Journal, 2008, Volume 2 Hann et al. 
 This method applies gradients which is similar in concept 
to typical gradient descent methods. The major difference is 
that no forward simulations are required so like the integral 
method [23] it is a computationally fast way of identifying 
large numbers of 
 
S
I
or other time-varying parameters. 
2.3. Controlling Drug Delivery 
 For the control of blood glucose G(t) in Equation (1), 
measurements are assumed to be taken every hour with a 
normally distributed absolute error of 7%, which is typical 
for a commercial glucometer [42]. Model-based control of 
glucose typically starts by taking two measurements G0 and 
G60 at the times 0 and 60 minutes and computing the insulin 
sensitivity SI from Equation (10). The goal is to determine 
the required insulin infusion uI or bolus uB in Equations (1) 
and (6) that will bring glucose down to a target value Gtarget 
in the next hour. 
 Let SI,1 be the solution of Equation (10) that determines 
the insulin sensitivity in the first hour. Define SI,2 as the insu-
lin sensitivity in the second hour. In the ICU a patient’s con-
dition can change rapidly as a result of a disease state or drug 
therapy. Therefore, SI can change significantly over time [2, 
23]. Given SI,1 in the first hour, it is thus possible that SI,2 in 
the second hour may have changed. An approximation to the 
insulin sensitivity SI,2 in the second hour for predicting po-
tential outcomes of an intervention at the end of hour 1, is 
defined SI ,2 = SI ,1 . As long as the true SI,2 doesn’t change 
significantly from SI,1, this value SI ,2 can be used to deter-
mine the insulin control input u(t) in Equation (1) that will 
bring the glucose to the target value of Gtarget. Any signifi-
cant changes will induce increasingly, unavoidable errors in 
the prediction. 
 First assume that 0=
B
u in Equation (6) and that only 
constant insulin infusion in the second hour is used. An ex-
ample is given in Fig. (1), which includes a “true” glucose 
response to an infusion of uI = 2  units over 1 hour with a 
nutritional input of P(t) = 0.03mmol/L/min. Insulin sensi-
tivity SI ,1 = 0.0008  (L/mU min), SI ,2 = 0.001 (L/mU min), 
GE=4.5 mmol and the rest of the parameters in Equation (1) 
are given in Equation (5). The “measurement” points G0=8 
and G60=7.26 are denoted by crosses (+) in Fig. (1) and the 
target glucose Gtarget=5 mmol/L is denoted by a circle (o). No 
noise is added. 
 For simplicity, it is assumed that SI is precisely known in 
the first hour. In practice, either the solution to Equation (10) 
or Equation (12) would approximate SI . Assuming that 
SI ,2 = 0.0008  in the second hour, the goal is to find the infu-
sion uI  such that the numerical solution G(t) to Equation (1) 
with SI=SI,2, and initial conditions, {G(0)=G60, Q(0)=Q60, 
I(0)=I60} satisfies G(60)=Gtarget. The values of Q60 and I60 are 
determined by the evaluating the numerical solution to Equa-
tions (2)-(3) at  t = 60 . Note that without loss of generality, 
the time at the beginning of drug intervention is assumed to 
be at 0 minutes and the target value is assumed to be at 60 
minutes. 
 
Fig. (1). Controlling glucose to a target value of Gtarget=5 mmol/L. 
The true
 
S
I
in the first and second hours are defined as 
 
S
I ,1
= 0.0008  and 
 
S
I ,2
= 0.001  (L/mU min). 
 To determine uI, Equation (1) is solved numerically for a 
range of infusion values uI, and the resulting end glucose 
value is compared to the target value. The end glucose value 
is represented as a function 
 
G
target
(u
I
) , and is defined: 
 
G
target
(u
I
) = G(60), G ? solution of Equations (1)-(3) with 
 
u(t) = u
I
          (13) 
 The correct 
 
u
I
is denoted 
 
u
I ,target
and is defined: 
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where 
 
G
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(u
I
) is defined in Equation (13). Define the 
points: 
 
u
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= (i ?1), i = 1,…,7 G
target ,i
= G
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(u
I ,i
), i = 1,…,7  (15) 
where 
 
u
I
 is treated as a variable on the y axis. Fig. (2) 
shows the points 
 
{(G
target ,1
,u
I ,1
),…, (G
target ,7
,u
I ,7
)}  plotted as 
crosses (+). A cubic spline is then fitted to the data, which is 
shown as the solid line in Fig. (2). Evaluating the cubic 
spline at 
 
G
target
 in Fig. (2) allows a good approximation to 
 
u
I ,target
 of Equation (14) with only 4 numerical solutions of 
Equations (1)-(3) required. This overall method for 
determining 
 
u
I ,target
 of Equation (14) is summarized in Fig. 
(3). 
 For this example, the target infusion was calculated to be 
 
u
I
= u
I ,target
= 3.27 U . The resulting glucose response with 
 
S
I
 held constant at the approximate value of 0.0008 L/mU 
min is denoted by a dashed line in Fig. (1). This approximate  
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Fig. (2). Plotting the points 
 
{(G
target ,1
,u
I ,1
),…, (G
target ,7
,u
I ,7
)}  
from Equation (16) and fitting a cubic spline to determine 
 
u
I ,target
 
in Equation (14). 
glucose response hits the target 
 
G
target
 as required. However, 
the “true” glucose response, which comes from using the 
output infusion 
 
u
I ,target
 in Fig. (2) with the true value of 
 
S
I ,2
= 0.001 , slightly undershoots 
 
G
target
 in Fig. (1). The end 
result in this case is still accurate, with an error of 8%. In 
practice both noise, modelling error and natural variation in 
 
S
I
 can effect the accuracy of hitting the target glucose and is 
investigated in detail in the results. 
2.4. Forward Simulation Based Methods and Summary 
 The most common approach to parameter identification 
as discussed in the introduction are methods that rely on 
many forward simulations. A standard non-linear regression 
least squares (NRLS) gradient descent algorithm was tested 
rigorously in [23]. Assuming a reasonable starting guess, the 
NRLS method was thousands of times slower than the 
integral method of [23]. Furthermore, local minima’s were 
often found so that the best insulin sensitivity estimate 
I
S was not always found. 
 The problem of local minima’s in NRLS can always be 
corrected by starting at many starting points, like the method 
of Cobelli [19]. However, this dramatically increases the 
number of forward simulations. For example in [23], the 
integral method was 1000 times fast than the NRLS 
algorithm which started from one initial guess. If 10-100 
starting points were used for the NRLS algorithm, which is 
quite typical to ensure accuracy (e.g. Cobelli [19]), the 
integral method would be 10000-100000 times faster than 
NRLS. The speed gain increases even further as the 
complexity of the model and number of fitted parameters 
increase, for example a cardiovascular model (e.g. [24, 26]). 
 For a model-based therapeutics approach [2, 9-14], the 
large number of forward simulations required in the NRLS 
approach is extremely costly, and is not feasible to imple-
ment. Note that an NRLS approach could be applied in the 
model-based control examples of this paper, and would give 
similar results to the integral method, but it comes at a con-
siderable computational cost. Therefore, since the model-
based therapeutics approach requires minimal computation, 
this paper focuses entirely on methods that do not require a 
forward simulation. The two methods considered are the 
derivative method of Equations (11) and (12) and the inte-
gral method of Equations (7)-(10). 
Fig. (3). An algorithm summarizing the method of model-based 
glucose control which determines the required insulin infusion that 
brings the blood glucose to a predetermined glucose target 
 
G
target
. 
Similar approaches can be used in appropriate time frames or 
intervals for any drug therapy that is similarly modelled with 
differential equations. 
 The derivative approach is a commonly used concept, for 
example in gradient descent algorithms, and would therefore 
most likely be the more easily understood and derived 
method. It is also perhaps, a more natural way of proceeding, 
since the original differential equation model is written in 
terms of derivatives. Therefore, the derivative approach at 
first sight would appear to be the simplest to implement and 
potentially a reasonable way of avoiding forward simulations 
in the parameter identification part of the model-based 
control algorithm of Fig. (3). 
 However, as is shown in the results, the integral 
formulation, which in general is perhaps a less known and 
accepted way of representing a differential equation model; 
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is in fact fundamental for reliable results. This phenomenon 
was also investigated in a related approach to parameter 
identification of a minimal cardiac model on clinical 
pulmonary embolism animal data [26], where even with 
perfectly smooth, model generated signals, a derivative 
approach went unstable. The integral approach on the other 
hand remained stable. 
 Hence, the main aim of this paper, is to investigate the 
effect of the two fast parameter identification integral and 
derivative based methods on the glucose-insulin model; and 
to better explain the importance of the integral in the 
formulation. Most importantly, this study is done in the 
context of model-based therapeutics and glucose control in 
the Christchurch Hospital Intensive Care Unit. 
3. RESULTS AND DISCUSSION 
 This section reviews the implementation of the integral 
method for long term model-based glucose control and 
compares the method with the similar approach that is based 
on the derivative. It thus contrasts the difference in using 
integrals and derivatives for this type of bio-engineering 
inspired parameter identification. The robustness of each 
formulation is investigated with respect to measurement 
noise and modelling error, intervention period, and number 
of measurements used. 
3.1. Glucose control in the Christchurch ICU 
 The glucose control protocol SPRINT [9, 10, 14, 32] is 
now used extensively in the Christchurch ICU. One of the 
keys to the success of SPRINT is the significant testing of 
model-based glucose control algorithms on “virtual” patients 
prior to implementation. The major physiological variable 
that is used to represent a “virtual” patient profile is the time 
varying insulin sensitivity 
 
S
I
= S
I
(t)  profile in Equation (1) 
that can be identified from retrospective data. 
 The integral-based parameter identification method [23] 
allowed fast and accurate insulin sensitivity profiles to be 
constructed for long term patient data. These profiles 
allowed an accurate physiological representation of a 
patient’s metabolic dynamics over periods of up to 1-2 
weeks [23], and were a fundamental element in the 
development of SPRINT [9, 10, 14, 32]. 
 The insulin sensitivity profiles provide a means to 
simulate physiologically realistic time varying glucose 
response to different insulin and nutrition regimes. This 
approach thus provides a repeatable cohort for easy 
comparison of various protocols. It also gives insight into 
long term clinical performance, and, importantly, lets 
algorithms and methods be tested safely before clinical 
implementation. 
 Fig. (4) shows a comparison of the “virtual clinical trials” 
versus the clinical data from the SPRINT trial in the 
Christchurch ICU for the first 16,000 clinical measurements 
and 24,000 hours of control. The distributions for the 
“virtual trials” are very close to both the raw SPRINT data 
and a lognormal fit of the data. The results of the virtual 
patient trials of other protocols [43-45] (not shown) also 
match their reports. The tightness of the SPRINT results and 
good correlation of other protocols serves as a significant 
validation of the methods and approach. 
Fig. (4). A comparison of the virtual trials approach and real 
clinical ICU results from SPRINT. Also shown are virtual patient 
simulations of two other well known protocols, Van den Berghe 
[46] and Krinsley [47]. 
 To further illustrate the impact of SPRINT, Fig. (5) 
shows a patient on SPRINT compared to a patient on a 
previously implemented clinical sliding scale in the 
Christchurch ICU. The measurements in both Fig. (5a) and 
(5b) are taken every hour, but the SPRINT patient is 
significantly better controlled than the patient on the original 
standard sliding scale. Note that the SPRINT patient also has 
2-4 potentially contaminated measurements but still provides 
better control to a 4-6.1 mmol/L or similar target band than 
the retrospective data patient who is less acutely ill by 
APACHE II score. 
3.2. Parameter Identification – Integral Versus 
Derivative 
 For ease of reference in this section and the following 
sections, Equations (7)-(10) are referred to as the Integral 
Method and Equations (11)-(12) are referred to as the 
Derivative Method. The methods are derived from the same 
set of differential Equations (1)-(3). Therefore, if no noise is 
present, it may be reasonable to suggest that they should 
perform equally well when identifying 
 
S
I
. In addition, 
neither requires the forward simulation used in most typical 
identification approaches. To test this assumption, the 
following set of parameters is considered: 
 
P = 0.08 mmol/(Lmin), U
i
=
100
3
mU/min,
U
b
= 0, S
I
= 0.0001 L/mU min
      (17) 
 “Measured” glucose values at  t = 0  and  t = 60  are 
generated by numerically solving Equations (1)-(3) for 
various values of 
 
G
E
, and initial conditions 
 
Q
0
 with a fixed 
initial glucose of 
 
G
0
= 5 mmol/L . Two main parameters sets 
are considered: 
 
G
E
= 4.5 mmol/L, 0 ? Q
0
? 20 mU/L        (18) 
 SPRINT 
clinical data 
and fitted 
 log normal SPRINT 
simulation 
Van den Berghe 
Krinsley 
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Q
0
= 8 mU/L, 3 ? G
E
? 15 mmol/L         (19) 
 In Equation (18), 
 
Q
0
 is varied in steps of 1 mU/L and in 
Equation (19), 
 
G
E
 is varied in steps of 1 mmol/L. Figs. (6) 
and (7) show the results of the identified 
 
S
I
 using the inte-
gral and derivative methods for each parameter set of Equa-
tions (18) and (19). 
 
Fig. (6). The identified insulin sensitivity 
 
S
I
 for the integral 
method of Equations (7)-(10) and derivative method of Equations 
(11)-(12) for the parameter set of Equation (18). 
 
Fig. (7). The identified insulin sensitivity 
 
S
I
 for the integral 
method of Equations (7)-(10) and derivative method of Equations 
(11)-(12) for the parameter set of Equation (19). 
 Fig. (6) shows that for 
 
Q
0
< 5 mU/L  the derivative 
method gives an 
I
S value that is significantly different from 
the true value. In fact it becomes non-physiological and 
negative for 
 
Q
0
= 0 and 1 . The integral method, in contrast, 
remains stable. Fig. (7) shows a similar result with the de-
rivative method rapidly diverging after 
 
G
E
= 4 mmol/L , and 
the integral method staying virtually constant. 
Fig. (5). (a) A patient (Patient 130) on a typical sliding scale before the use of SPRINT in the Christchurch ICU. APACHE II score = 11. (b) 
A patient (Patient 5005) on SPRINT in the Christchurch ICU. APACHE II score = 21. 
(b) 
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 The scenarios of Figs. (6) and (7) can be realized in prac-
tice whenever the insulin is cut off, so that Q(t) reaches low 
levels, followed by an increase of carbohydrate input (see 
example to follow). In particular, a negative 
 
S
I
 would occur 
whenever the true 
 
S
I
 is sufficiently low, so that the typical 
undershooting that occurs with the derivative method goes 
less than zero, as the example in Fig. (6) demonstrates. 
3.2.1. Model-based Glucose Control Example – Minimizing 
Insulin Infusion 
 To demonstrate the results of Figs. (6) and (7) in a clini-
cal setting, a patient from the retrospective cohort of [23] is 
considered. The patient used is Patient 554, who was a fe-
male aged 20; type 1 diabetic; medical subgroup – Other 
Medical; APACHE II score - 26. Seven hours of data is ana-
lyzed, and Fig. (8) shows the time-varying insulin sensitivity 
for this period taken from [23]. Patient 554 also has the pa-
rameters: 
 
G
E
= 4.5 mmol/L and G
0
= 5.4 mmol/L   (20) 
and all the other parameters are defined in Equation (5). 
 
Fig. (8). Time varying insulin sensitivity for Patient 554 from the 
retrospective cohort [23]. 
 To begin the model-based control algorithm of Fig. (3), 
two glucose values are required in the first hour. These val-
ues are generated by solving Equations (1)-(4) with the pa-
rameters of Equation (5) and (20); an insulin infusion input 
of 
 
u
I
= 0.5 U , u
B
= 0  for 
 
u(t)  in Equation (6); and initial 
conditions for insulin defined, by 
 
I
0
= 1  mU/min, 
 
Q
0
= 1  
mU/min. The target glucose in Step 4 of Fig. (3) is 
 
G
target
= 5 mmol/L . Additional constraints for this example, 
are that the use of exogenous insulin 
 
u
I
 is minimized and is 
only in steps of 0.5 U, and that when possible, the carbohy-
drate input 
 
P(t) , is the primary controller with a resolution 
of 0.01 mmol/L/min. Finally, it is assumed that for hour 6 
the feed is increased to 0.06 mmol/L/min. 
 The identified insulin sensitivity for each of the deriva-
tive and integral methods is shown in Fig. (9), along with the 
true insulin sensitivity of Fig. (8). Notice that even without 
noise, both parameter identification methods deteriorate at 
hours 5 and 6, but the integral method is the most accurate. 
The absolute percentage errors of the methods for hours 1-6 
in Fig. (9) are: 
 
error
derivative
= 1.3, 10.5, 5.6, 0.4, 34, 55.2?? ?? (%)
error
integral
= [3.5, 6.9, 3.0, 0.8, 19.7, 13.0] (%)
      (21) 
 This deterioration is a result of low insulin levels which 
progressively removes the effect of 
 
S
I
 on the glucose re-
sponse, and thus the large errors in 
 
S
I
 have a negligible ef-
fect on glucose control, which is shown in hours 1-6 of Fig. 
(10). This state of no insulin and very little carbohydrate 
input, of course could not be sustained for any significant 
period of time, as the patient would face malnutri-
tion/starvation. Thus, the feed is increased at hour 6. 
Fig. (9). The identified insulin sensitivity values for the derivative 
and integral methods compared to the true insulin sensitivity for 
Patient 554. 
 There is no reliable insulin sensitivity value from the 
prior hour due to the very low insulin levels. Therefore, a 
conservative infusion of 0.5 mmol/L/min is applied at hour 6 
to identify insulin sensitivity so that the algorithm of Fig. (3) 
can be applied accurately in the following hour. Fig. (9) and 
Equation (21) show that the integral method identifies the 
insulin sensitivity quite accurately at hour 6 with an error of 
13.0%, where the derivative method has a much larger error 
of 55.2%. 
 However, the significant under prediction of insulin sen-
sitivity for the derivative method dramatically affects con-
trol. Fig. (10) shows that control in hour 7 for the derivative 
method is poor, with a 5.5 mU bolus predicted and an unde-
sirable, and potentially dangerous, hypoglycaemia event of 
3.61 mmol/L. This result corresponds to an error of 27.8% in 
the target glucose. On the other hand, the control based on 
the integral method is good with a final glucose value of 4.83 
mmol/L, which corresponds to a 3.4% error. The results of 
Figs. (9) and (10) further confirm the observations of Figs. 
(6) and (7). 
 Note that the scenario of Fig. (10) is not uncommon in 
critical care and for the extended retrospective data set given 
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in Shaw et al. [48], can occur several times daily. Therefore, 
the integral method allows more flexibility in the control 
protocol by not requiring insulin infusion to be on con-
stantly, and is robust to sudden increases in the carbohydrate 
input. 
 
Fig. (10). Model-based glucose control using the algorithm of Fig. 
(3), with the added constraint of minimizing the exogeneous insu-
lin. 
3.2.2. Model-Based Glucose Control – Constant SI 
Approximation 
 To further test the methods for a longer period and to 
demonstrate the practical, clinical issues associated with 
model-based control, another patient from the retrospective 
data of [23] is used. The patient is Patient 519, who was a 
male aged 69; type 2 diabetic; medical subgroup - General 
Surgical; APACHE II score - 29. The integral and derivative 
methods are compared based on a constant 
 
S
I
, which is 
taken to be the mean 
 
S
I
 of patient 519. Similarly, the pa-
rameters 
 
P(t)  and 
 
G
E
 in Equations (1)-(4) are set constant 
at the mean nutritional input and mean glucose respectively 
of patient 519. The numerical values of the parameters are 
thus defined: 
 
S
I
= 9.28 ?10?4 L/mU min , 
 
P(t) = 0.049  mmol/(Lmin), 
 
G
E
= 5.84  mmol/L         (22) 
 The rest of the model parameters are defined in Equation 
(5). Data for the first 3 days of patient 519 is used to test the 
predictive model-based glucose control of Fig. (3). Note that 
the protocol of minimizing the insulin, which was imple-
mented in Fig. (9), is not used. 
 To begin the model-based control algorithm of Fig. (3), 
two glucose values are required in the first hour. These val-
ues are generated by solving Equations (1)-(4) with the pa-
rameters of Equation (22); an insulin infusion input of 
 
u
I
= 1 U , u
B
= 0  for 
 
u(t)  in Equation (6); and initial condi-
tions of 
 
G
0
= 11.5  mmol/L, 
 
I
0
= 0  mU/min, 
 
Q
0
= 0  
mU/min. The target glucose in Step 4 of Fig. (3) is defined: 
 
G
target
= max{G
0
?1,5}          (23) 
where for each consecutive hour the initial conditions 
 
G
0
, 
 
I
0
 and 
 
Q
0
 are taken as the previously calculated 
 
G
60
, 
 
Q
60
 
and 
 
I
60
, as detailed in Step 2 of Fig. (3). Equation (23) en-
sures the reductions in glucose are not too large which clini-
cally, may be undesirable for the patient. 
 Every hour that the algorithm of Fig. (3) is applied, a new 
infusion 
 
u
I ,target
 is defined for the next hour, which in turn 
defines a new glucose response, and so on as long as re-
quired. In this example, the final time is at 3 days or 72 
hours, which gives 71 intervention periods since the first 
period is just a fitting period. Importantly, the size of the 
infusion cannot be greater than 6 Units [11, 13] for patient 
safety. To be physiologically realistic it must be also greater 
than 0. Therefore, the infusion 
 
U
I ,target
 in Fig. (3) is con-
strained: 
 
0 ?U
I ,target
? 6U           (24) 
 The results of the algorithm of Fig. (3) for the integral 
method of Equations (7)-(10) are shown in Fig. (11a), where 
7% uniformly distributed noise is placed on the hourly glu-
cose measurements to mimic the sensor error in the glu-
cometer [11, 13, 23]. All measurements in Fig. (11a) lie in 
the 4-6.1 mmol/L band showing that very tight glucose con-
trol is achieved when 
 
S
I
 is constant. Fig. (11b) shows the 
results of using the derivative method of Equations (11)-(12) 
in place of the integral method in Step 3 of Fig. (3). Again 
all measurements lie in the 4-6.1 mmol/L band, showing 
there is virtually no difference between the methods. 
 The result of Figs. (11a,b) shows that for Patient 519, the 
parameter regimes of Equations (18) and (19) that caused 
instability for the derivative method in Figs. (6) and (7), 
were not realized. The mean value of 
 
Q(t)  during this “vir-
tual trial” of patient 519 was 16.5 mU/min. Examining Fig. 
(6), it can be seen that for these relatively high 
 
Q(t)  values 
the derivative and integral methods behave similarly. 
3.3. Model-Based Glucose Control – Time Varying 
 
S
I
 
 The results of Fig. (11) show that with continual insulin 
infusions over time the derivative and integral methods per-
form similarly in glucose control with hourly measurements 
of glucose. Therefore, since the main differences in control 
have already been investigated in Fig. (10), the comparison 
of the derivative and integral methods is discontinued in this 
section. 
 The insulin sensitivity profile of Patient 519 as fitted in 
[23] is highly dynamic, and the first three days are shown in 
Fig. (12). To demonstrate the practical aspects of model-
based glucose control, the algorithm of Fig. (3) is applied to 
the time varying 
 
S
I
 of Fig. (12) using the integral method. 
Note that in [38, 39] and Lin 2007 [49], the integral method 
has been well validated and proven for extensive numbers of 
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virtual patients, therefore no further patients other than Pa-
tient 519 are tested in this paper. 
 
Fig. (11). (a) Algorithm of Fig. (3), with the integral method of 
Equations (7)-(10)used in Step 3. (b) Algorithm of Fig. (3), with the 
derivative method of Equations (11)-(12) used in Step 3. 
 The nutritional input 
 
P(t)  is again held constant with all 
other parameters the same as given in Equations (5) and  
(22). 
 
Fig. (12). Time varying 
 
S
I
 profile over first 3 days for patient 519. 
 Fig. (13) gives the result for the integral method, which 
shows that glucose control is significantly worse than Fig. 
(11). The mean glucose and standard deviation of  5.58 ±1.03  
mmol/L with 67.57% of glucose values lying in the 4.0 to 
6.1 mmol/L band. Very similar results are obtained for the 
derivative method, so these results are not shown. 
 The reason for this decrease in performance is explained 
by the insulin infusion graph of Fig. (14). There are signifi-
cant periods in Fig. (14) where the insulin has reached the 
maximum of 6 Units/hour so effectively no added, but nec-
essary, control is being applied in these periods and insulin 
effect is saturated [2, 36]. The solution to this problem has 
been to vary the nutrition, as well as the insulin [9, 10]. A 
fully developed and validated method for modulating both 
the nutrition and insulin in a model-based glycemic control 
system is detailed in [13, 14]. 
 To demonstrate the essential concept the nutrition is 
dropped to 40% of the original value, whenever the insulin 
hits the upper limit of 6 units. A new insulin infusion is then 
calculated in Step 4 of Fig. (3) for this reduced nutrition. 
This simple rule results in a significant improvement in glu-
cose control as shown in Fig. (15). The mean glucose is 
 5.32 ± 0.67  mmol/L with 76.14% of values lying between 4 
and 6.1 mmol/L. 
 
Fig. (13). Model-based glucose control with the time varying 
 
S
I
 of 
Fig. (12) and a fixed nutritional input given in Equation (22). 
 
 
Fig. (14). Control infusion input 
 
u
I ,target
 in Step 4 of Fig. (3), for 
the model-based glucose control of Fig. (13). 
3.4. Combining CGMS with Glucocard Measurements 
 To demonstrate a new clinical application of the methods 
presented and to further investigate the comparison of the 
integral versus derivative approaches, a CGMS sensor is 
included in the model-based glucose control algorithm. The 
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CGMS sensor measures glucose every 5 minutes with a 
measurement error that can be approximated by the formula 
[34]: 
 
G
noise
= (1+ 0.18? )G
true
, ? ?  normal distribution 
 
(μ = 0,? = 1)           (25) 
 Equation (25) gives a mean absolute error of 14%, which 
is typical for CGMS sensors [41, 50]. 
 
Fig. (15). Model-based glucose control with the time varying 
 
S
I
 of 
Fig. (12) and a simply varying nutritional input. 
 Blood glucose is still assumed to be measured hourly 
with a glucocard and 7% uniformly distributed noise in addi-
tion to the CGMS for comparison. To account for the extra 
noise in the CGMS and to give the greatest chance for an 
averaging effect on the errors, insulin sensitivity
I
S is fitted 
over the prior 1? hours rather than 1 hour, as was presented 
in Fig. (3). The intervention period is also shortened to ? 
hour to take advantage of the extra measurements from 
CGMS. The 1? hour periods ensure that 2 glucocard meas-
urements will always be available to fit 
 
S
I
 when stepping 
along each interval of ? hour. 
 The same algorithm of Fig. (3) is applied, except the in-
tegral and derivative methods are implemented over the 
longer 1? hour period and the infusion 
 
U
I ,target
 in Step 4 of 
Fig. (3) is updated every ? hour. A further change that is 
made is that 7% low frequency modelling error is added to 
the glucose measurements, as well as the normally distrib-
uted error in Equation (25). The final expression for noise is 
thus defined: 
 
G
noise
= (1+ 0.18? ) 1? 0.07 cos 2?
82
t
?
??
?
??
?
??
?
?? Gtrue       (26) 
 Equation (26) reflects the fact that a higher resolution in 
measurements, trades off with both a higher amount of sen-
sor error and importantly, modelling error. 
 The modelling error is caused by potentially missed dy-
namics in the glucose-insulin model of Equations (1)-(3). 
Simple oscillations are used as an initial proof of concept 
since low frequency oscillations have been often observed in 
both glucose and 
 
S
I
 [23]. However, further work must be 
done on real CGMS data to fully characterize the tradeoff’s 
in the error. 
 Fig. (16) shows the resulting glucose control for Patient 
519 using the same parameters as used for Fig. (15). A sig-
nificant improvement can be seen with a mean glucose of 
 5.03± 0.42  mmol/L and 98.55% of glucose values lying 
between 4 and 6.1 mmol/L. 
 Fig. (17) shows the first 12 hours of data with both the 
CGMS data and glucocard data plotted against the true glu-
cose. The “true glucose” is denoted by the solid line and in-
cludes the modelling error of Equation (26), but not the sen-
sor error, so that  ? = 0  in Equation (24). The widely spread 
points are the simulated CGMS data which are plotted every 
5 minutes using the formula in Equation (24) with ? nor-
mally distributed as given in Equation (23). The circles are 
the simulated glucocard hourly “measurements” which put 
7% random uniformly distributed noise on the “true glu-
cose”. 
 
Fig. (16). Model-based glucose control using the integral method in 
Step 3 of Fig. (3), with the combination of a CGMS sensor and 
glucocard. 
 The derivative method is now used in place of the inte-
gral method in Step 3 of Fig. (3). The same data is used, but 
to potentially assist the derivative method, the data is 
smoothed several times by a 3 point moving average. How-
ever, even with smoothing to remove most of the local noise, 
a significantly worse result is seen in Fig. (18). The mean 
glucose is  5.5 ±1.1  mmol/L with only 64.86% of glucose 
values lying between 4.0 and 6.1 mmol/L. Thus, the deriva-
tive method is unable to take advantage of the extra CGMS 
data, where the integral method gives significantly better 
outcomes on glucose control despite the larger noise distri-
bution for these sensors. The derivative method clearly per-
forms better when there is very minimal modelling error and 
the true glucose is close to a straight line between two points, 
which was the case in Figs. (11,13,15), but does not occur 
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with significant sensor noise and/or modelling error, both of 
which typically exist. 
 
Fig. (17). The first 12 hours (720 minutes) of patient 519, with 
simulated CGMS data shown as points, glucocard “measurements” 
shown in circles and a solid line denoting the “true glucose” which 
includes the modelling error of Equation (26), but not the sensor 
error. 
 
 
Fig. (18). Model-based glucose control using the derivative method 
instead of the integral method in Step 3 of Fig. (3), and with a 
CGMS sensor and glucocard. 
CONCLUSIONS 
 This paper has reviewed the model-based therapeutics 
approach to glucose control that has been developed and put 
into regular use in the Christchurch Hospital, New Zealand 
ICU, and investigated the impact of two different fast pa-
rameter identification methods. The key point with these 
parameter identification methods is that unlike typical non-
linear regression approaches, they do not require any forward 
numerical solutions to identify model parameters. They are 
also not starting point dependent, and thus provide a major  
 
advantage in the implementation of model-based “virtual” 
clinical trials as well as significant real-time capability. The 
two methods considered were a previously developed inte-
gral-based patient specific parameter identification method 
and a similar approach based on the derivative. At first sight 
it might be expected that the integral and derivative ap-
proaches would perform similarly given they are derived 
from the same underlying differential equation model. How-
ever, even without noise significant differences were ob-
served for certain parameter sets and glucose control proto-
cols, with the integral method remaining significantly more 
robust. 
 A number of tests were performed on clinically derived 
data from a patient in the Christchurch ICU. Very little dif-
ferences were observed between the model-based glucose 
control using the integral method compared to the derivative 
method for this patient. This result is due to the fact that the 
insulin levels remained quite constant and high throughout, 
so that the insulin dynamics between measurements were 
minimal. The resulting glucose response was thus very close 
to a straight line with very little modelling error. However, 
when adding extra measurements from CGMS along with 
low frequency modelling error, the derivative method per-
formed very poorly, and had worse results than without the 
CGMS. The integral method on the other hand remained 
robust and gave a significant improvement in glucose con-
trol. 
 The overall results are summarized as follows. 
• The integral formulation in parameter identification is 
very important for robust and reliable results, particu-
larly with respect to modelling error which is always 
present in clinical applications 
• The derivative method is very sensitive to modelling 
error and only works in situations where model re-
sponse is close to a straight line. 
• The combination of the integral method and model-
based drug control is very effective for designing and 
testing new protocols. 
 The integral method is an important research tool in the 
model-based therapeutics approach. For example the addi-
tion of simulated CGMS shows that a potentially significant 
clinical gain could be achieved with this continuous sensor. 
However, further investigation with real CGMS data is re-
quired to validate these results. The derivative method, went 
unstable and failed to realize this possible clinical gain, fur-
ther emphasizing the importance of integrals in the formula-
tion. 
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